Company: INDP
Filing Date: 2025-09-02
Form Type: 424B5
Source: 0001493152-25-012530
Chunk: 1

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: 424B5
Chunk 1
---
 no arrangement for funds to be received in any escrow, trust or similar arrangement.

We will pay Wainwright a commission equal to 3.0% of the gross sales price per share of common stock issued by us and sold through it as Sales Agent. In connection with the sale of the shares of common stock on our behalf, Wainwright will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of Wainwright will be deemed to be underwriting commissions or discounts. This offering pursuant to this prospectus supplement will terminate upon the earlier of (1) the sale of common stock pursuant to this prospectus supplement having an aggregate sales price of $2,340,000 and (2) the termination by us or the Sales Agent of the Offering Agreement pursuant to its terms.

Our shares of common stock are traded on the Nasdaq Capital Market under the symbol “INDP.” The last reported sale price of our shares of common stock, as reported on the Nasdaq Capital Market on August 29, 2025 was $6.50.

The aggregate market value of our outstanding common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 was $13,440,372, which was calculated based on 1,106,529 shares of common stock outstanding, as of September 2, 2025, of which 62,211 shares were held by non-affiliates, and a price per share of $12.87 which was the closing sale price of our common stock on the Nasdaq Capital Market on July 9, 2025. Pursuant to General Instruction I.B.6. of Form S-3, in no event will we sell securities pursuant to the registration statement with a value more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-calendar-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75.0 million. During the prior 12-calendar-month period that ends on, and includes, the date of this prospectus supplement, we have sold an aggregate of $2,134,995 of securities pursuant to General Instruction I.B.6. of Form S-3.

Investing in our shares of common stock involves risks. See the section entitled “ Risk Factors” beginning on page S-5 of this prospectus supplement and in the documents we incorporate by reference into this prospect